Division of Cardiac Surgery, The Johns Hopkins University, Baltimore, Maryland.
Division of Cardiac Surgery, The Johns Hopkins University, Baltimore, Maryland.
Ann Thorac Surg. 2020 Jan;109(1):78-84. doi: 10.1016/j.athoracsur.2019.05.038. Epub 2019 Jul 4.
Left ventricular assist devices (LVADs) are the most common mode of circulatory support for patients awaiting heart transplantation. Unfortunately, a fraction of these patients require pump exchange during their course for pump-related adverse events. This study examined whether LVAD exchanges affect posttransplantation outcomes.
This study focused on adult patients in the Organ Procurement and Transplantation Network database who were bridged to transplant with a LVAD implanted between 2007 and 2017. Patients who underwent LVAD exchange were compared with those supported with a single device. The primary end point was all-cause mortality at 1, 2, and 5 years after transplantation. The impact of device exchange on risk-adjusted outcomes was examined using Cox proportional hazards models.
Among 8239 patients who met the inclusion criteria, there were 611 pump exchanges in 560 patients (7% of recipients). The pump exchange rate was 6.24 events per 100 patient-years. Survival at 5 years was lower for those who underwent LVAD exchange (69.4% vs 77.5%, log-rank P = .027). This finding was similar for risk-adjusted 5-year mortality (hazard ratio, 1.36; 95% confidence interval, 1.11 to 1.67; P = .003). Subgroup analysis revealed lower 5-year survival for female recipients who underwent LVAD exchange (55.4% vs 79.7%, log-rank P < .001). The interaction between female sex and LVAD exchange was associated with increased risk-adjusted 5-year mortality (hazard ratio, 1.65; 95% confidence interval, 1.05 to 2.59; P = .030).
Recipients who underwent pump exchange while awaiting heart transplantation had a higher mortality compared with those on a primary device. Subgroup analysis revealed a marked increase in mortality of female recipients who experienced LVAD exchange.
左心室辅助装置(LVAD)是等待心脏移植的患者最常见的循环支持方式。不幸的是,其中一部分患者在其病程中因泵相关不良事件需要更换泵。本研究探讨了 LVAD 更换是否会影响移植后的结果。
本研究专注于 2007 年至 2017 年期间在器官获取与移植网络数据库中接受 LVAD 桥接移植的成年患者。将接受 LVAD 更换的患者与接受单一装置支持的患者进行比较。主要终点是移植后 1、2 和 5 年的全因死亡率。使用 Cox 比例风险模型检查设备更换对风险调整后结果的影响。
在符合纳入标准的 8239 名患者中,有 560 名患者(占受者的 7%)进行了 611 次泵更换。泵更换率为每 100 患者年 6.24 例。接受 LVAD 更换的患者 5 年生存率较低(69.4%比 77.5%,log-rank P =.027)。这一发现与风险调整后 5 年死亡率相似(风险比,1.36;95%置信区间,1.11 至 1.67;P =.003)。亚组分析显示,接受 LVAD 更换的女性受者 5 年生存率较低(55.4%比 79.7%,log-rank P <.001)。女性性别与 LVAD 更换之间的相互作用与风险调整后 5 年死亡率增加相关(风险比,1.65;95%置信区间,1.05 至 2.59;P =.030)。
等待心脏移植时接受泵更换的受者死亡率高于初次使用装置的受者。亚组分析显示,经历 LVAD 更换的女性受者死亡率明显增加。